Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™
15 juin 2021 07h30 HE
|
Ocugen
MALVERN, Pa., June 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial
10 juin 2021 07h35 HE
|
Ocugen
MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen to pursue a BLA path in the US for its COVID-19 vaccine candidate
10 juin 2021 07h30 HE
|
Ocugen
Company intends to work with the FDA towards filing a Biologics License Application (BLA) in the USCompany to engage with Health Canada to seek authorization under Interim Order for use in Canada ...
Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada
03 juin 2021 07h30 HE
|
Ocugen
Ocugen to have exclusive co-development, manufacturing, and commercialization rights to COVAXIN™ in Canada, in addition to its existing US rights MALVERN, Pa. and HYDERABAD, India, June 03, 2021 ...
Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™
26 mai 2021 20h06 HE
|
Ocugen
Active discussions with FDA related to COVAXIN initiated late last yearMaster file submitted to FDA on March 26, 2021; awaiting feedback from FDA MALVERN, Pa., May 26, 2021 (GLOBE NEWSWIRE) --...
Ocugen Provides Business Update and First Quarter 2021 Financial Results
07 mai 2021 07h30 HE
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET COVAXIN demonstrates 100% efficacy against severe COVID-19 disease (including hospitalization)Master File submitted for U.S. Food and Drug...
Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update
03 mai 2021 16h35 HE
|
Ocugen
MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...